Arcturus Therapeutics (NASDAQ:ARCT) Announces Earnings Results, Beats Estimates By $0.16 EPS

Key Points

• Arcturus beat quarterly EPS estimates, reporting a loss of $0.84 per share versus the expected $1.00 loss, though revenue of $2.96 million fell short of the $3.11 million consensus.
• Clinical progress continued, with ARCT-810 completing Phase II enrollment and dosing; data and regulatory updates are expected in Q3 2026, while a Phase III decision for ARCT-032 is planned for Q4 2026.
• Revenue plunged to approximately $3 million from $28.3 million year over year as the CSL collaboration ended, but Arcturus regained global rights to KOSTAIVE and related vaccine assets and said its cash runway extends through 2028.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16, FiscalAI reports. The company had revenue of $2.96 million during the quarter, compared to analysts' expectations of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 44.42%.

Here are the key takeaways from Arcturus Therapeutics' conference call:

• ARCT-810 completed Phase II enrollment and dosing in OTC deficiency, with U.S. and European data expected in Q3 2026 alongside FDA-requested supplementary data and an update on the regulatory path for adult and pediatric development.
• ARCT-032’s Phase II cystic fibrosis study remains on schedule, supported by expanded enrollment in Israel and Turkey; Arcturus expects to decide whether to advance to Phase III in Q4 2026, which would trigger substantial manufacturing and development support from Thermo Fisher.
• Arcturus regained global rights to KOSTAIVE and its broader self-amplifying mRNA vaccine portfolio after ending the CSL Seqirus collaboration. The settlement included a $12 million cash payment and release from approximately $16 million in liabilities, while returning strategic control that could enable commercialization and new partnerships.
• Revenue fell sharply to $3 million in Q2 2026 from $28.3 million a year earlier as the CSL collaboration wound down, while cash declined to $191.5 million from $230.8 million at year-end 2025.
• Management said the company has more than two and a half years of cash runway through year-end 2028, but it will need to balance rare-disease clinical spending with efforts to commercialize or partner the returned vaccine assets.

Arcturus Therapeutics Trading Up 21.9%

ARCT stock traded up $1.33 during midday trading on Friday, hitting $7.41. 1,461,125 shares of the company's stock were exchanged, compared to its average volume of 442,082. The business has a 50-day simple moving average of $6.77 and a two-hundred day simple moving average of $7.38. The stock has a market capitalization of $210.59 million, a PE ratio of -2.24 and a beta of 2.39. Arcturus Therapeutics has a 1-year low of $5.50 and a 1-year high of $24.17.

Wall Street Analyst Weigh In

ARCT has been the topic of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. Wall Street Zen lowered Arcturus Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $24.25.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its holdings in Arcturus Therapeutics by 51.8% during the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 27.5% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company's stock valued at $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company's stock valued at $3,805,000 after buying an additional 2,098 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock valued at $54,000 after buying an additional 2,586 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in shares of Arcturus Therapeutics by 3.3% in the 3rd quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company's stock valued at $1,644,000 after buying an additional 2,857 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus's approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company's pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source